[go: up one dir, main page]

BR0314584A - Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4 - Google Patents

Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4

Info

Publication number
BR0314584A
BR0314584A BR0314584-0A BR0314584A BR0314584A BR 0314584 A BR0314584 A BR 0314584A BR 0314584 A BR0314584 A BR 0314584A BR 0314584 A BR0314584 A BR 0314584A
Authority
BR
Brazil
Prior art keywords
groups
group
pharmaceutically acceptable
compound
compounds
Prior art date
Application number
BR0314584-0A
Other languages
English (en)
Inventor
Yasuhiro Katsu
Kon-I Kana
Mikio Morita
Hirohide Noguchi
Chikara Uchida
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32030864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0314584(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of BR0314584A publication Critical patent/BR0314584A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTOS PIPERIDINIL-IMIDAZOPIRIDINA NSUBSTITUìDA COMO MODULADORES DE RECEPTORES 5-HT~ 4~". A presente invenção refere-se a um composto de fórmula (I): onde R^ 1^ representa um átomo de hidrogênio ou um átomo de halogêneo; R^ 2^ representa um átomo de hidrogênio, etc; R^ 3^ representa um grupo alquila com desde 1 até 10 átomos de carbono; onde o referido grupo alquila em R^ 3 ^ é substituído por pelo menos um substituinte selecionado de um grupo consistindo em substituintes (x, os referidos substituintes a são selecionado de um grupo consistindo em grupos arila, grupos hidróxi, grupos oxo, etc; os referidos grupos arila com 6 a 10 átomos de arbono, os referidos grupos heterocíclicos e porções hetecíclicas nos grupos heterociclicarbonilas são grupos cíclicos e 5- a 10-membros contendo desde 1 a 4 heteroátomos selecionados de um grupo consistindo em átomos de nitrogênio, etc.; ou uma amida desse composto famaceuticamente aceitável, ou um éster desse composto famaceuticamente aceitável, e seus sais desse composto famaceuticamente aceitáveis. Estes compostos tem atividade e ligação ao receptor 5-HT~ 4~, e deste modo são úteis no tratamento de doença de refluxo gastroesofágica, dispepsia não ulcerosa, dispepsia funcional, síndrome do intestino irritável ou de doenças semelhantes em mamíferos, especialmente no homenm. Esta invenção também proporciona uma composição farmacêutica compreendendo o composto acima.
BR0314584-0A 2002-09-20 2003-09-08 Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4 BR0314584A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41242602P 2002-09-20 2002-09-20
PCT/IB2003/003945 WO2004026868A1 (en) 2002-09-20 2003-09-08 N-substituted piperidinyl-imidazopyridine compounds as 5-ht4 receptor modulators

Publications (1)

Publication Number Publication Date
BR0314584A true BR0314584A (pt) 2005-08-09

Family

ID=32030864

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314584-0A BR0314584A (pt) 2002-09-20 2003-09-08 Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4

Country Status (13)

Country Link
US (1) US6951867B2 (pt)
EP (1) EP1543004A1 (pt)
JP (1) JP2006502180A (pt)
AR (1) AR041303A1 (pt)
AU (1) AU2003259482A1 (pt)
BR (1) BR0314584A (pt)
CA (1) CA2499494A1 (pt)
GT (1) GT200300208A (pt)
MX (1) MXPA05003065A (pt)
PA (1) PA8582901A1 (pt)
TW (1) TW200406412A (pt)
UY (1) UY27992A1 (pt)
WO (1) WO2004026868A1 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1620435A1 (en) * 2003-04-21 2006-02-01 Pfizer Inc. IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY
JP4704353B2 (ja) * 2003-11-24 2011-06-15 ファイザー株式会社 5−ht4受容体アゴニスト活性を有するキノリンカルボン酸化合物
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
EP1758891A2 (en) * 2004-06-15 2007-03-07 Pfizer Japan Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
ATE441646T1 (de) 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
JP5042028B2 (ja) 2004-11-05 2012-10-03 セラヴァンス, インコーポレーテッド キノリノン−カルボキサミド化合物
CA2588037A1 (en) 2004-12-22 2006-06-29 Theravance, Inc. Indazole-carboxamide compounds
US7446114B2 (en) 2005-03-02 2008-11-04 Theravance, Inc. Quinolinone compounds as 5-HT4 receptor agonists
MY147756A (en) 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
GB0603550D0 (en) * 2006-02-22 2006-04-05 Glaxo Group Ltd Novel compounds
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009023253A2 (en) * 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US20100272680A1 (en) * 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
CN102762201B (zh) 2009-11-06 2013-12-18 爱思开生物制药株式会社 注意力缺陷/多动症的治疗方法
CN107260736A (zh) * 2010-02-12 2017-10-20 株式会社AskAt 用于治疗痴呆的5‑ht4受体激动剂
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
IL252053B2 (en) 2014-11-06 2024-04-01 Lysosomal Therapeutics Inc SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
US11124516B2 (en) 2016-04-06 2021-09-21 BIAL-BioTech Investments, Inc. Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR20180133461A (ko) 2016-04-06 2018-12-14 리소소말 테라퓨틱스 인크. 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
MX389579B (es) 2016-05-05 2025-03-20 Bial R&D Invest S A IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS
US11345698B2 (en) * 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
GB2589573A (en) 2019-12-02 2021-06-09 Caterpillar Inc Bucket actuator assembly with resilient bump stop

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851423A (en) 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
JP2643274B2 (ja) 1988-04-08 1997-08-20 三菱化学株式会社 イミダゾ〔1,2−a〕ピリジン誘導体
FR2646894B3 (fr) * 1989-05-11 1991-07-12 Sleever Int Procede pour controler la temperature dans un four-tunnel ouvert a ses deux extremites, et dispositif pour la mise en oeuvre du procede
US5137893A (en) 1991-03-07 1992-08-11 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5196547A (en) 1991-03-07 1993-03-23 G. D. Searle & Co. Meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5219850A (en) 1991-03-07 1993-06-15 G. D. Searle & Co. Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
GB9221468D0 (en) * 1992-10-13 1992-11-25 Smithkline Beecham Plc Pharmaceuticals
AU3192295A (en) 1994-08-11 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Substituted amine derivative and medicinal composition containing the same
AU703203B2 (en) 1996-01-30 1999-03-18 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997038665A2 (en) 1996-04-03 1997-10-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
MXPA00009569A (es) 1998-03-31 2002-08-06 Acadia Pharm Inc Compuestos con actividad en receptores muscarinicos.
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
WO2003035649A1 (en) * 2001-10-22 2003-05-01 Pfizer Japan Inc. Imidazopyridine compounds as 5-ht4 receptor modulators
US6624162B2 (en) * 2001-10-22 2003-09-23 Pfizer Inc. Imidazopyridine compounds as 5-HT4 receptor modulators

Also Published As

Publication number Publication date
US6951867B2 (en) 2005-10-04
TW200406412A (en) 2004-05-01
MXPA05003065A (es) 2005-05-27
WO2004026868A1 (en) 2004-04-01
EP1543004A1 (en) 2005-06-22
AU2003259482A1 (en) 2004-04-08
UY27992A1 (es) 2004-04-30
US20040127514A1 (en) 2004-07-01
CA2499494A1 (en) 2004-04-01
GT200300208A (es) 2004-05-20
PA8582901A1 (es) 2004-05-26
AR041303A1 (es) 2005-05-11
JP2006502180A (ja) 2006-01-19

Similar Documents

Publication Publication Date Title
BR0314584A (pt) Compostos piperidinil-imidazopiridina n-substituìda como moduladores e receptores 5-ht4
BR0314284A (pt) Compostos de imidazopiridina como agonistas do receptor 5-ht4
DE602005005167D1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3-carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
BR0300018A (pt) Compostos oxo ou oxi-piridina como moduladores do receptor 5-ht4
AU572405B2 (en) Heterocyclic-substituted indole
BR0010391A (pt) Composto, composição farmacêutica, método de preparação de um composto, e, uso de um composto
BRPI0707491B8 (pt) compostos úteis como agentes moduladores de receptores de mineralocorticóides, os referidos agentes compreendendo os mesmos e composições farmacêuticas
EA199800394A1 (ru) Пиразолпиримидины как антагонисты крф рецепторов
ATE164575T1 (de) Substituierte aromatische verbindungen als c. amp phosphodiesterase-und tnf-hemmer
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
ATE63914T1 (de) N6-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
CZ290784B6 (cs) Pyrido[3,2-e]pyrazinony, způsoby jejich výroby a pouľití a farmaceutické přípravky na jejich bázi
BR0210733A (pt) Derivados de piperidina de utilidade úteis como moduladores da atividade do receptor de quimocina
ATE461192T1 (de) Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung
BRPI0409592A (pt) compostos imidazopiridina tendo atividade agonìstica do receptor 5-ht4 e atividade antagonìstica do receptor 5-ht3
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
BR0016953A (pt) Derivados de 4-fenil-1-piperazinila, -piperidinila e tetraidropiridila substituìdo por halogênio, composto, composição farmacêutica, uso e método de tratamento
BRPI0415109A (pt) compostos de 1-[2-(4-hidroxifenil)-2-hidroxietil]-piperidin-4-ol como antagonistas de receptor de nmda
AR018632A1 (es) Compuestos derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene, proceso para su preparacion.
CA2016665A1 (en) Rhodanine derivatives and pharmaceutical compositions
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
ZA200702878B (en) Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and method of making them
NO903084D0 (no) Farmasoeytisk anvendbare thiazol-derivater og fremgangsmaate for deres fremstilling.
DOP2003000717A (es) Compuestos de piperidinil-imidazopiridina n-sustituidos como moduladores del receptor 5ht4
NO934881L (no) Benzotiazolderivater, fremgangsmåte for deres fremstilling og farmasöytisk preparat derav

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]